These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 30290289)

  • 1. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Cannon CP; McGuire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG;
    Am Heart J; 2018 Dec; 206():11-23. PubMed ID: 30290289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.
    Pratley RE; Cannon CP; Cherney DZI; Cosentino F; McGuire DK; Essex MN; Lawrence D; Jones PLS; Liu J; Adamsons I; Dagogo-Jack S
    Lancet Healthy Longev; 2023 Apr; 4(4):e143-e154. PubMed ID: 37003273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
    Cannon CP; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Masiukiewicz U; Charbonnel B; Frederich R; Gallo S; Cosentino F; Shih WJ; Gantz I; Terra SG; Cherney DZI; McGuire DK;
    N Engl J Med; 2020 Oct; 383(15):1425-1435. PubMed ID: 32966714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
    Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
    Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart K; Carris NW
    Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
    Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
    Wojeck BS; Inzucchi SE; Neeland IJ; Mancuso JP; Frederich R; Masiukiewicz U; Cater NB; McGuire DK; Cannon CP; Yaggi HK
    Sleep Breath; 2023 May; 27(2):669-672. PubMed ID: 35596030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
    Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Green JB; Hernandez AF; D'Agostino RB; Granger CB; Janmohamed S; Jones NP; Leiter LA; Noronha D; Russell R; Sigmon K; Del Prato S; McMurray JJV
    Am Heart J; 2018 Sep; 203():30-38. PubMed ID: 30015066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
    Dagogo-Jack S; Frederich R; Liu J; Cannon CP; Shi H; Cherney DZI; Cosentino F; Masiukiewicz U; Gantz I; Pratley RE
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2042-2051. PubMed ID: 36702781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
    Corbin KD; Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Frederich R; Liu J; Pong A; Lin J; Cater NB; Pratley RE
    Diabetes Obes Metab; 2023 Mar; 25(3):758-766. PubMed ID: 36394384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
    Diabetes Obes Metab; 2022 Jul; 24(7):1245-1254. PubMed ID: 35266296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
    Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
    Diabetes Obes Metab; 2022 Jun; 24(6):1114-1122. PubMed ID: 35233908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.